Inclusion Criteria  Participants are eligible to be included in the study only if all of the following criteria apply:  Histologically or cytologically confirmed: Cutaneous SCC, Head and Neck SCC, Melanoma, Merkel Cell Carcinoma, NSCLC, Renal Cell Carcinoma, or Urothelial Carcinoma. Other tumor types will be allowed at Sponsor's discretion. Tumor progression on the most recent line of treatment with anti-PD-1 or anti-PD-L1 mAb as monotherapy or in combination. Eastern Cooperative Oncology Group (ECOG) score of 0 - 2 At least 1 lesion with measurable disease at baseline Availability of a lesion for biopsy and consent to allow pre-treatment tumor biopsy.  Exclusion Criteria  Participants are excluded from the study if any of the following criteria apply:  Greater than 4 lines of prior DNA-damaging chemotherapies. Uncontrolled CNS metastases. Active autoimmune disease.  Other protocol defined inclusion/exclusion criteria could apply